163 related articles for article (PubMed ID: 24604684)
1. Long-term therapy of benign essential blepharospasm and facial hemispasm with botulinum toxin A: retrospective assessment of the clinical and quality of life impact in patients treated for more than 15 years.
Streitová H; Bareš M
Acta Neurol Belg; 2014 Dec; 114(4):285-91. PubMed ID: 24604684
[TBL] [Abstract][Full Text] [Related]
2. [Results of long term treatment of essential blepharospasm and facial hemispasm with botulinum toxin A].
Ziak P
Cesk Slov Oftalmol; 2004 Jan; 60(1):37-44. PubMed ID: 15011305
[TBL] [Abstract][Full Text] [Related]
3. Long-term botulinum toxin treatment of benign essential blepharospasm, hemifacial spasm, and Meige syndrome.
Czyz CN; Burns JA; Petrie TP; Watkins JR; Cahill KV; Foster JA
Am J Ophthalmol; 2013 Jul; 156(1):173-177.e2. PubMed ID: 23541393
[TBL] [Abstract][Full Text] [Related]
4. [Treatment of blepharospasm, hemifacial spasm and facial synkinesis with botulinum toxin].
Winterhoff J; Laskawi R
HNO; 2012 Jun; 60(6):479-83. PubMed ID: 22669435
[TBL] [Abstract][Full Text] [Related]
5. Long-term efficacy of botulinum toxin A for treatment of blepharospasm, hemifacial spasm, and spastic entropion: a multicentre study using two drug-dose escalation indexes.
Cillino S; Raimondi G; Guépratte N; Damiani S; Cillino M; Di Pace F; Casuccio A
Eye (Lond); 2010 Apr; 24(4):600-7. PubMed ID: 19648904
[TBL] [Abstract][Full Text] [Related]
6. Low-dose treatment of cervical dystonia, blepharospasm and facial hemispasm with albumin-diluted botulinum toxin type A under EMG guidance. An open label study.
Rollnik JD; Matzke M; Wohlfarth K; Dengler R; Bigalke H
Eur Neurol; 2000; 43(1):9-12. PubMed ID: 10601802
[TBL] [Abstract][Full Text] [Related]
7. [Treatment of blepharospasm and facial hemispasm by injection of botulinum toxin].
Saraux H
J Fr Ophtalmol; 1988; 11(3):237-40. PubMed ID: 3418019
[TBL] [Abstract][Full Text] [Related]
8. Quality of life in hemifacial spasm patient after treatment with botulinum toxin A; a 24-week, double-blind, randomized, cross-over comparison of Dysport and Neuronox study.
Kongsengdao S; Kritalukkul S
J Med Assoc Thai; 2012 Mar; 95 Suppl 3():S48-54. PubMed ID: 22619887
[TBL] [Abstract][Full Text] [Related]
9. [Essential blepharospasm and hemifacial spasm: characteristic of the patient, botulinum toxin A treatment and literature review].
Schellini SA; Matai O; Igami TZ; Padovani CR; Padovani CP
Arq Bras Oftalmol; 2006; 69(1):23-6. PubMed ID: 16491229
[TBL] [Abstract][Full Text] [Related]
10. [Treatment of blepharospasm and facial hemispasm with botulinum toxin. Apropos of 58 injections in 22 patients].
Elbaz D
Ann Otolaryngol Chir Cervicofac; 1994; 111(3):141-4. PubMed ID: 7840486
[TBL] [Abstract][Full Text] [Related]
11. Impact on quality of life of botulinum toxin treatments for essential blepharospasm.
MacAndie K; Kemp E
Orbit; 2004 Dec; 23(4):207-10. PubMed ID: 15590520
[TBL] [Abstract][Full Text] [Related]
12. Blepharospasm and hemifacial spasm: long-term treatment with botulinum toxin.
Gil Polo C; Rodríguez Sanz MF; Berrocal Izquierdo N; Castrillo Sanz A; Gutiérrez Ríos R; Zamora García MI; Mendoza Rodríguez A; Duarte García-Luis J
Neurologia; 2013 Apr; 28(3):131-6. PubMed ID: 22652139
[TBL] [Abstract][Full Text] [Related]
13. Electrical activation of the orbicularis oculi muscle does not increase the effectiveness of botulinum toxin type A in patients with blepharospasm.
Conte A; Fabbrini G; Belvisi D; Marsili L; Di Stasio F; Berardelli A
Eur J Neurol; 2010 Mar; 17(3):449-55. PubMed ID: 19968711
[TBL] [Abstract][Full Text] [Related]
14. [Focal dystonias and facial hemispasm: treatment with botulinum A toxin].
Astarloa R; Morales B; Sánchez V; Peñafiel N; Rábano J; Oliván J; García de Yébenes J
Arch Neurobiol (Madr); 1991; 54 Suppl 3():44-51. PubMed ID: 1810208
[TBL] [Abstract][Full Text] [Related]
15. [Focal dystonias and facial hemispasm: treatment with botulinum A toxin].
Astarloa R; Morales B; Sánchez V; Peñafiel N; Rábano J; Oliván J; García de Yébenes J
Arch Neurobiol (Madr); 1991; 54(5):210-7. PubMed ID: 1804035
[TBL] [Abstract][Full Text] [Related]
16. Patient-reported benefit from botulinum toxin treatment for essential blepharospasm: using 2 assessment scales.
Lee RM; Chowdhury HR; Hyer JN; Smith HB; Jones CA
Ophthalmic Plast Reconstr Surg; 2013; 29(3):196-7. PubMed ID: 23446304
[TBL] [Abstract][Full Text] [Related]
17. Quantitative changes in botulinum toxin a treatment over time in patients with essential blepharospasm and idiopathic hemifacial spasm.
Snir M; Weinberger D; Bourla D; Kristal-Shalit O; Dotan G; Axer-Siegel R
Am J Ophthalmol; 2003 Jul; 136(1):99-105. PubMed ID: 12834676
[TBL] [Abstract][Full Text] [Related]
18. Long-term efficacy of botulinum a toxin for blepharospasm and hemifacial spasm.
Gill HS; Kraft SP
Can J Neurol Sci; 2010 Sep; 37(5):631-6. PubMed ID: 21059510
[TBL] [Abstract][Full Text] [Related]
19. [Botulinum toxin therapy for focal dystonia].
Hahn K; Niklai E; Garzuly F; Szupera Z
Orv Hetil; 2009 Jul; 150(29):1381-4. PubMed ID: 19581172
[TBL] [Abstract][Full Text] [Related]
20. Comparison of two different formulations of botulinum toxin A for the treatment of blepharospasm and hemifacial spasm.
Wu CJ; Shen JH; Chen Y; Lian YJ
Turk Neurosurg; 2011; 21(4):625-9. PubMed ID: 22194126
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
